NewAmsterdam Pharma Company N.V. (NAMS)

Over the past six months, NewAmsterdam Pharma's stock has shown significant growth, with its share price increasing. Investor engagement included a fireside chat at the Needham Virtual Healthcare Conference. Recent announcements included presentations at healthcare conferences and inducement grants. Presentations at the American College of Cardiology Annual Scientific Session led to a gain in the stock. The company reported its Full Year 2025 Financial Results, missing analyst estimates. Insider selling activity was observed. Institutional interest remains evident. Broader market sentiment has impacted the stock. Positive clinical progress for obicetrapib contributed to gains. The company announced the acceptance of Marketing Authorization Applications for review by the European Medicine Agency for obicetrapib. Positive data from the BROADWAY trial were presented at AAIC 2025. The CEO highlighted the completion of Phase III trials, publications, and an early signal of MACE reduction in the BROADWAY trial.

As a late-stage clinical biopharmaceutical company, NewAmsterdam Pharma does not have established demand seasonality for its products and services, as its primary product is still in clinical development and not yet commercialized. The company's focus is on research, development, and regulatory approvals rather than commercial sales.

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company in the Healthcare sector, focusing on Drug Discovery within the Biotechnology and Pharmaceutical Products industry. The company aims to improve patient care for individuals with metabolic diseases through its primary product candidate, obicetrapib, a CETP inhibitor being developed as a monotherapy and in combination with ezetimibe for lowering LDL-C and is also being investigated for Alzheimer's disease.

NewAmsterdam Pharma is incorporated in the Netherlands, with headquarters in Naarden. Its shares are listed on the Nasdaq Stock Market under the ticker NAMS. The company aims for global product availability and has partnered with Menarini for exclusive commercialization rights of obicetrapib in Europe.

NewAmsterdam Pharma generally maintains a positive brand reputation, particularly within the investment community, with a consensus rating of "Moderate Buy" from analysts. Its reputation is supported by positive market reactions to clinical progress and data readouts for obicetrapib. Scientific publications in prestigious journals contribute to its scientific credibility. Stock price fluctuations and insider selling are viewed as market dynamics rather than direct impacts on the company's core brand reputation.

NewAmsterdam Pharma has a significant institutional ownership base, with 188 institutional owners holding a large number of shares. Major institutional owners include Frazier Life Sciences Management and Capital World Investors. Institutional shareholders account for a large percentage of ownership, while insiders hold a smaller percentage. James N. Topper is the largest individual insider shareholder. Retail investor ownership is reported as 0.00%.